Publikationen 2016
Kletting P, Kull T, Maaß C, Malik N, Luster M, Beer AJ, Glatting G.
Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy
J Nucl Med. 2016Apr;57(4):503-8
http://jnm.snmjournals.org/content/57/4/503.long
Verburg FA, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, Iakovou I, Mihailovic J, Krause BJ, Langsteger W, Luster M
Why the European Association of Nuclear Medicine has declined to
endorse the 2015 American Thyroid Association management guidelines for adult
patients with thyroid nodules and differentiated thyroid cancer.
Eur J Nucl MedMol Imaging. 2016 Jun;43(6):1001-5. (Editorial)
https://link.springer.com/article/10.1007%2Fs00259-016-3327-3
Treglia G, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, Iakovou I,
Mihailovic J, Krause BJ, Langsteger W, Verburg FA, Luster M;
The 2015 Revised American Thyroid Association guidelines for
the management of medullary thyroid carcinoma: the "evidence-based" refusal to
endorse them by EANM due to the "not evidence-based" marginalization of the role
of Nuclear Medicine.
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1486-90. (Editorial)
https://link.springer.com/article/10.1007%2Fs00259-016-3404-7
Verburg FA, Luster M, Giovanella L.
Adjuvant post-operative I-131 therapy in differentiated thyroid carcinoma: are the 2015 ATA guidelines an exact science or a dark art?
Eur J Nucl Med Mol Imaging. 2016 Oct 10. (Editorial)
https://link.springer.com/article/10.1007%2Fs00259-016-3526-y
Weber T, Gottstein M, Schwenzer S, Beer A, Luster M.
Is C-11 Methionine PET/CT Able to Localise Sestamibi-Negative Parathyroid Adenomas?
World J Surg. 2016 Nov
https://link.springer.com/article/10.1007%2Fs00268-016-3795-4
Giovanella L1,2, D'Aurizio F3, Campenni' A4, Ruggeri RM5, Baldari S4, Verburg FA6,7, Trimboli P8, Ceriani L8.
Searching for the most effective thyrotropin (TSH) threshold to rule-out autonomously functioning thyroid nodules in iodine deficient regions.
Endocrine. 2016 Dec;54(3):757-761. Epub 2016 Sep 15.
https://link.springer.com/article/10.1007%2Fs12020-016-1094-3
Liu L, Zheng M, Librizzi D, Renette T, Merkel OM, Kissel T.
Efficient and Tumor Targeted siRNA Delivery by Polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate(PEI-PCL-PEG-Fol).
Mol Pharm. 2016 Jan 4;13(1):134-43.
https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5b00575
Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarani HR, Schmidt M, Bartenstein P, Pfestroff A, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ.
German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients.
J NuclMed. 2016 Oct 20.
http://jnm.snmjournals.org/content/58/1/85.long
Teymoortash A, Pfestroff A, Wittig A, Franke N, Hoch S, Harnisch S,
Schade-Brittinger C, Hoeffken H, Engenhart-Cabillic R, Brugger M, Strauch K.
Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after
Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized,
Placebo-Controlled, Double-Blinded Phase I Clinical Trial.
PLoS One. 2016 Mar18;11(3):e0151316.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798778/
Gratz S, Reize P, Kemke B, Kampen WU, Luster M, Höffken H.
Targeting osteomyelitis with complete [99mTc]besilesomab and fragmented [99mTc]sulesomab
antibodies: kinetic evaluations.
Q J Nucl Med Mol Imaging. 2016 Dec;60(4):413-23.
https://www.minervamedica.it/en/journals/nuclear-med-molecular-imaging/article.php?cod=R39Y2016N04A0413
Feldkamp J, Führer D, Luster M, Musholt TJ, Spitzweg C, Schott M
Fine Needle Aspiration in the Investigation of Thyroid Nodules.
Dtsch Arztebl Int. 2016 May20;113(20):353-9.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906830/
Dietlein M, Eschner W, Grünwald F, Lassmann M, Verburg FA, Luster M.
[Procedure guidelines for radioiodine therapy of differentiated thyroid cancer.
Version 4].
Nuklearmedizin. 2016 Jun 28;55(3):77-89.
https://eanm.org/publications/guidelines/
gl_radio_ther_259_883.pdf
Bodei L, Modlin IM, Luster M, Forrer F, Cremonesi M, Hicks RJ, Ezziddin S,
Kidd M, Chiti A.
Myeloid neoplasms after chemotherapy and PRRT: myth and reality.
Endocr Relat Cancer. 2016 Aug;23(8):C1-7.
https://erc.bioscientifica.com/view/journals/erc/23/8/C1.xml
Verburg FA, Pfestroff A.
Imaging: PSMA PET-CT in initial prostate cancer staging.
Nat Rev Urol. 2016 Sep;13(9):498-9.
https://www.nature.com/articles/nrurol.2016.136
Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M,
Pfestroff A, Lützen U, Prasad V, Heinzel A, Heuschkel M, Ruf J, Bartenstein P,
Krause BJ.
[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with
metastatic castration-resistant prostate cancer].
Nuklearmedizin. 2016 Jun28;55(3):123-8. German.
https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0037-1616480
Verburg FA1, Van Santen HM2, Luster M1.
Pediatric papillary thyroid cancer: current management challenges.
Onco Targets Ther. 2016 Dec 28;10:165-175. doi: 10.2147/OTT.S100512. eCollection 2017.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207438/